Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease

Marzia Palma, MD PhD, Tom A. Mulder, MD, Kia Heimersson, Li-Sophie Rathje, PhD, Thomas Olin, MSc,PhD, Johan Schultz, MSc,PhD, Håkan Mellstedt, MD PhD, Anders Österborg, MD PhD

Blood (2019) 134 (Supplement_1): 5445.

https://doi.org/10.1182/blood-2019-121818

Published: 2019

Journal Articles

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Marzia Palma, MD PhD, Kia Heimersson, Tom A. Mulder, MD, Barbro Näsman-Glaser, Anders Österborg, MD PhD Prof., Håkan Mellstedt, MD PhD

Blood (2018) 132 (Supplement 1): 4421.

https://doi.org/10.1182/blood-2018-99-110236

Published: 2018

Journal Articles

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Andreas T Björklund, MD PhD MSc, Mattias Carlsten, MD PhD, Ebba Sohlberg, PhD, Trevor Clancy, Lisa Liu, Mohsen Karimi, PhD, Sarah Cooley, MD, Jeffrey S. Miller, MD, Emma Watz, Björn Engelbrekt Wahlin, Marzia Palma, MD PhD, Lotta Hansson, Per Ljungman, Eva Hellstrom-Lindberg, MD PhD, Hans-Gustaf Ljunggren, Karl-Johan Malmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4458.

https://doi.org/10.1182/blood.V130.Suppl_1.4458.4458

Published: 2017

Journal Articles

Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3 + and CD8 + T Cells and Immune Checkpoints Expression but Gradually Leads to CD4 + T-Cell Depletion

Marzia Palma, MD PhD, Kia Heimersson, Barbro Näsman-Glaser, Håkan Mellstedt, MD PhD, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 4322.

https://doi.org/10.1182/blood.V130.Suppl_1.4322.4322

Published: 2017

Journal Articles

Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Marzia Palma, MD PhD, Aleksandra Krstic, PhD, Anna Berglöf, PhD, Qing Wang, PhD, Emelie Blomberg, PhD, Stephan Meinke, PhD, Masood Kamali-Moghaddam, PhD, Qiujin Shen, PhD, Georg Jaremko, MD PhD, Jeanette Lundin, MD PhD, Eva Kimby, MD professor, Petter Höglund, MD PhD, Robert Månsson, PhD, Anders Österborg, MD PhD, Edvard Smith, PhD

Blood (2016) 128 (22): 3235.

https://doi.org/10.1182/blood.V128.22.3235.3235

Published: 2016

Journal Articles

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Maria Winqvist, MD, Fariba Mozaffari, PhD, Marzia Palma, MD PhD, Sandra Eketorp Sylvan, MD PhD, Hakan Mellstedt, MD PhD, Anders Osterborg, MD PhD, Jeanette Lundin, MD PhD

Blood (2015) 126 (23): 4164.

https://doi.org/10.1182/blood.V126.23.4164.4164

Published: 2015

Journal Articles

Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients

Lotta Hansson, MD PhD, Marzia Palma, MD PhD, Lars Adamson, Harriet Ryblom, Barbro Näsman-Glaser, Ingrid Eriksson, Kia Heimersson, Giusy Gentilcore, Håkan Mellstedt, MD PhD, Anders Österborg

Blood (2014) 124 (21): 4685.

https://doi.org/10.1182/blood.V124.21.4685.4685

Published: 2014

Journal Articles

Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta

Dhifaf Sarhan, PhD, Marzia Palma, MD PhD, Yumeng Mao, Lars Adamson, Rolf Kiessling, MD PhD, Håkan Mellstedt, MD PhD, Anders Österborg, Andreas Lundqvist

Blood (2014) 124 (21): 4140.

https://doi.org/10.1182/blood.V124.21.4140.4140

Published: 2014

Journal Articles

Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

Andreas T Björklund, MDPhD, Mattias Carlsten, MD PhD, Marie Schaffer, PhD, Lisa Liu, MD, Sarah A. Cooley, MD MS, Jeffrey S. Miller, MD, Emma Watz, MD, Marzia Palma, MD PhD, Lotta Hansson, MD PhD, Björn E Wahlin, MD PhD, Lars Möllgård, MDPhD, Hans Hagglund, MD PhD, Pontus Blomberg, PhD, Per T. Ljungman, MD PhD, Eva Hellström-Lindberg, MD PhD, Hans-Gustaf Ljunggren, MD PhD, Karl-Johan Malmberg, MD, PhD

Blood (2014) 124 (21): 1120.

https://doi.org/10.1182/blood.V124.21.1120.1120

Published: 2014

Journal Articles

Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)

Marzia Palma, MD, PhD, Parviz Kokhaei, PhD, Lotta Hansson, MD, PhD, Mohammad Hojat-Farsangi, PhD, Aniruddha Raja Choudhury, PhD, Anders Osterborg, MD, PhD, Håkan Mellstedt, MD, PhD

Blood (2010) 116 (21): 2413.

https://doi.org/10.1182/blood.V116.21.2413.2413

Published: 2010

Journal Articles

T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.

Eva Rossmann, MD, PhD, Parviz Kokhaei, PhD, Fariba Mozaffari, PhD, Marzia Palma, MD, Anders Osterborg, MD, PhD, Hakan Mellstedt, MD, PhD, A. Raja Choudhury, MSc, PhD

Blood (2008) 112 (11): 2071.

https://doi.org/10.1182/blood.V112.11.2071.2071

Published: 2008

NARROW

Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Long-Term Treatment with Ibrutinib in Chronic Lymphocytic Leukemia Patients Normalizes CD3 + and CD8 + T Cells and Immune Checkpoints Expression but Gradually Leads to CD4 + T-Cell Depletion

Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients

Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta

Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)

T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only